This document has been redacted by Sam Collaudin, Kinexum Business Strategy Consultant, independently from any pharmaceutical and biotech companies - It synthesizes selected data presented during the ATTD 2021 conference
- Grey rectangles are personal comments and opinions, underlined words are clickable links to other slides or external references
- If you have comments, please contact me by email (This email address is being protected from spambots. You need JavaScript enabled to view it.)
- Disclosure: Business strategy consultant at Modular Medical, CEO of Abvance Kinexum , consultant for Therapeutics, chairman of a non for profit French health care insurance company (Groupe Operating Since 2003 Uitsem)
SUBSCRIBE
Biohealth Innovation
Founding Member of
